Homburger advised CDR-Life in the transaction. CDR-Life Inc, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, announced the closing...
This content is for Standard 1 Year members only. LoginJoin Now